|
Renalytix PLC shares soared on Wednesday after the company said it launched its new provider access portal myIntelX in the UK.
Shares shot up 16% to 332.00 pence each on Wednesday morning in London.
The London-based diagnostics company focused on the management of kidney disease said myIntelX will provide online access for physicians to order testing with KidneyIntelX bioprognostic, its clinical diagnostic tool for diabetic kidney disease.
The access portal can streamline ordering and reporting for current testing locations across the US, it explained.
Renalytix added that this will enable more accurate identification of patients with type 2 diabetes patients with the greatest risk for rapid progression of kidney disease.
The company said that the access portal is being launched in conjunction with KidneyIntelX testing at Charlotte, North Caroline - headquartered hospital network Atrium Health.
In May, the Renalytix teamed up with Atrium Health Wake and likewise North Carolina-based Forest Baptist Health and Wake Forest School of Medicine to implement an advanced clinical care model to improve kidney health.
‘Virtual capability provided through our myIntelX portal is an important step towards expanding access nationally to the KidneyIntelX proprietary technology,’ Renalytix President Tom McLain said.
‘myIntelX now makes simple, early-stage risk assessment available online for practices that might not otherwise have access to KidneyIntelX integrated ordering through our large-scale health system partnerships.’
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
